Fundraising FoxSanofi Ventures — 2023 Investments
5 investments dated 2023 · listed companies and verified rows first · show all
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsAdjuvant CapitalIndustrifondenOrbiMedPureos BioventuresSunstone CapitalEQT Life Sciences+2 more
Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.
BiotechDigital HealthHealthtechMedical DevicesSacramento, US
Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in
BoardOlga Danilchanka(Director)inLaia Crespo-Martin(Director)
Co-investorsMRL Ventures FundSV Health InvestorsAngelini VenturesDementia Discovery FundDolby Family VenturesMitsui Global Investment+2 more
Eligo Bioscience is a genetic engineering company pioneering synthetic biology approaches using CRISPR and phage biology to develop therapeutics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
David Bikard(Scientific Founder)Benoit Barteau(Scientific Cofounder)Nessan Bermingham(Scientific Cofounder)Laia Crespo-Martin(Scientific Cofounder)Xavier Duportet(CEO)
Co-investorsAgoranovNSG VenturesSeventure PartnersVIVES Partners
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Founder, Chief Executive Officer)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsALS Investment FundDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMission Biocapital+8 more
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Co-investorsFrazier Life SciencesMonograph Capital PartnersPICUS CAPITALSV Health InvestorsDementia Discovery FundFrazier Healthcare Partners+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.